From owner-chemistry@ccl.net Thu Feb 26 08:17:01 2015 From: "Rene Thomsen rene.thomsen{=}qiagen.com" To: CCL Subject: CCL: CLC bio releases CLC Drug Discovery Workbench 2.0 Message-Id: <-51063-150226055912-26938-ziKQv31kp/J0aAD/e5swEg(0)server.ccl.net> X-Original-From: "Rene Thomsen" Date: Thu, 26 Feb 2015 05:59:11 -0500 Sent to CCL by: "Rene Thomsen" [rene.thomsen*o*qiagen.com] Aarhus, Denmark February 26th, 2015 CLC bio, a QIAGEN Company is pleased to announce a new release of CLC Drug Discovery Workbench, an enterprise drug-design platform for medicinal and computational scientists available for Windows, Linux, and Mac OS X. CLC Drug Discovery Workbench offers access to atomic level insights in protein-ligand interaction, and allows new ideas for improved binders to be quickly tested and visualized. New feature highlights in version 2.0: * Homology modeling. A new homology modeling tool makes it possible to go from amino acid sequence to structure model in two steps. * Single point mutations. Amino acids can now be mutated or repaired in the 3D view of the protein structure. * Constraints in Ligand Optimizer tool. This enables optimization of covalently bound ligands while preserving well-established binding interactions. * Integrated sequence and structure analysis. Protein 3D structures can now be linked to sequences or sequence alignments, and annotations can be transferred between sequence and 3D structure. If you want to try CLC Drug Discovery Workbench, a 14-days trial is available from http://www.clcbio.com/products/clc-drug-discovery-workbench/ Contact CLC bio, a QIAGEN Company: Lea Thgersen, Senior Scientist & Product Manager Phone: +45 3840 0564 E-mail: lea.thoegersen*_*qiagen.com About CLC bio, a QIAGEN Company: http://www.clcbio.com/corporate/about-clc-bio/